No benefit for TS-1/irinotecan combo in second-line gastric cancer
This article was originally published in Scrip
Adding Taiho Pharmaceutical's TS-1 to irinotecan for the second-line treatment of gastric cancer patients refractory to first-line TS-1 therapy confers no survival benefit over irinotecan alone, new summary results from a Japanese Phase III trial show.
You may also be interested in...
Japan bioventure BioComo was set up around 10 years ago and has since been honing its technology platform. It is now preparing to move into the clinic with a novel vector for immuno-oncology and to raise new funds to support pipeline development.
While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.
Highly promising results for a novel, easy to use form of CAR therapy, as early trial in hematologic malignancies shows a high response and low toxicity.